<DOC>
	<DOCNO>NCT02597868</DOCNO>
	<brief_summary>A multi-sites study efficacy sequential monotherapy : Capecitabine vs. endocrine therapy , metastatic breast cancer patient HR-positive &amp; HER2-negative capecitabine-base chemotherapy .</brief_summary>
	<brief_title>A Multicenter , Randomized Clinical Trail Evaluate Effectiveness Security Capecitabine Endocrinotherapy Maintenance Therapy Regimen After 1st-line Chemotherapy With Capecitabine Combine Regimen Hormone Receptor Positive HER2 Negative Metastatic Breast Cancer ( Overstep )</brief_title>
	<detailed_description>capecitabine-base chemotherapy must first-line chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Signed informed consent The age Above 18 year age , &lt; 70 year old HRpositive &amp; HER2negative Metastatic breast cancer , incurable . No prior chemotherapy metastatic recurrence , disease progression within 6 month end adjuvant chemotherapy , adjuvant chemotherapy firstline treatment metastatic lesion Eastern Cooperative Oncology Group performance status ( ECOG PS ) =0~1 The basic function normal bone marrow Functions liver kidney normal Expectation life 3 month Agreed take contraceptive measure treatment Previous toxicity recover 01 degree Central nervous system metastasis Pregnancy lactation There uncontrolled infection , myocardial infarction , thrombosis , etc . There uncontrolled chronic disease diabetes , hypertension , peptic ulcer , chronic hepatitis , mental disease ; Researchers believe suitable study Patients malignant tumor history , except heal skin basal cell carcinoma carcinoma uterine cervix ; Bilateral breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>therapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>breast cancer</keyword>
</DOC>